Scholar Rock (SRRK) affiliated fund adds 500,439 shares in Oct 2025

Rhea-AI Filing Summary

Srinivas Akkaraju, a director, reported multiple purchases of Scholar Rock Holding Corp (SRRK) common stock in early October 2025. The filings show net additions through affiliated vehicles, primarily Samsara Opportunity Fund, L.P., bringing the fund's reported beneficial ownership to 500,439 shares following purchases executed on 10/03/2025 and 10/06/2025. Purchase prices are disclosed as weighted averages across multiple trades, with reported ranges from $35.14 up to $39.84 depending on the tranche. The report also notes prior shares held by Samsara BioCapital, L.P. and contains standard disclaimers that the reporting person disclaims beneficial ownership except to the extent of pecuniary interest.

Positive

• Significant net purchases reported that increase the affiliated fund's stake to 500,439 shares
• Purchases executed across multiple dates (10/03/2025 and 10/06/2025), showing sustained buying activity
• Transparent pricing disclosure with weighted-average price ranges provided for each tranche

Negative

• Indirect ownership structure—shares are held by affiliated funds, and the reporting person disclaims beneficial ownership except for pecuniary interest
• Concentration in affiliated vehicles may limit clarity on the individual director's personal economic exposure

Insights

Equity Capital Markets Analyst

Material insider purchases concentrated in an affiliated fund raise reported stake to 500,439 shares.

The transactions were purchases executed on 10/03/2025 and 10/06/2025

and were recorded at weighted average prices ranging from $35.14 to $39.84. The buying activity is aggregated under Samsara Opportunity Fund, L.P., which the reporting person controls. For investors, the key mechanic is that these are fund-level acquisitions, not direct purchases by the individual, so voting and investment power are exercised through the fund.

Risks and dependencies include the indirect ownership structure and the reporting person’s disclaimer of beneficial ownership except for pecuniary interest, which limits how the purchases translate to the individual's personal exposure. Monitor quarterly disclosures and any Schedule 13 filings for changes in direct ownership or changes to the fund’s stake within Q4 2025.

Corporate Governance Specialist

Form 4 shows standard Section 16 reporting for a director with affiliated-entity holdings and disclaimers.

The filing identifies the reporter as a director and lists purchases attributed to controlled entities (Samsara Opportunity Fund and Samsara BioCapital). The form includes customary explanatory footnotes about weighted average prices and disclaimers of beneficial ownership where the reporter claims only pecuniary interest.

Governance implications: these entries should be read as fund-managed activity rather than unequivocal personal accumulation. Watch for any future amendments or related-party disclosures that change the characterization of voting or dispositive power in the near term (next SEC filing cycle).

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AKKARAJU SRINIVAS

(Last) (First) (Middle)

628 MIDDLEFIELD ROAD

(Street)

PALO ALTO CA 94301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Scholar Rock Holding Corp [ SRRK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/03/2025		P		11,011	A	$35.61(1)	11,011	I	By Samsara Opportunity Fund, L.P.(2)
Common Stock	10/03/2025		P		56,703	A	$36.74(3)	67,714	I	By Samsara Opportunity Fund, L.P.(2)
Common Stock	10/03/2025		P		319,700	A	$37.42(4)	387,414	I	By Samsara Opportunity Fund, L.P.(2)
Common Stock	10/06/2025		P		18,414	A	$37.89(5)	405,828	I	By Samsara Opportunity Fund, L.P.
Common Stock	10/06/2025		P		80,863	A	$38.68(6)	486,691	I	By Samsara Opportunity Fund, L.P.(2)
Common Stock	10/06/2025		P		13,748	A	$39.52(7)	500,439	I	By Samsara Opportunity Fund, L.P.(2)
Common Stock								21,132	D
Common Stock								5,302,810(8)	I	Samsara BioCapital, L.P.(9)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $35.14 to $36.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

2. Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

3. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $36.14 to $37.1391 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $37.14 to $37.6227 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $37.23 to $38.2276 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $38.23 to $39.2298 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $39.23 to $39.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

8. The shares held by Samsara BioCapital, L.P. ("Samsara LP") reflect the disposition of 310,086 shares previously reported as held by Samsara LP, in which the Reporting Person had no pecuniary interest. The transfer of such shares by Samsara LP did not involve a change in the Reporting Person's beneficial ownership of such shares and, accordingly, was exempt from reporting under Section 16.

9. Shares held by Samsara LP. The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

	/s/ Srinivas Akkaraju	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SRRK director Srinivas Akkaraju report on Form 4?

He reported multiple purchases through affiliated entities that increased the fund-level beneficial ownership to 500,439 shares following trades on 10/03/2025 and 10/06/2025.

At what prices were the SRRK shares purchased?

The filing discloses weighted-average price ranges for tranches, with purchases reported between $35.14 and $39.84 across the transactions.

Are these purchases held directly by the director?

No; the reported shares are held indirectly by Samsara Opportunity Fund, L.P. and Samsara BioCapital, L.P., and the director disclaims beneficial ownership except to the extent of pecuniary interest.

How many shares were added on 10/03/2025?

On 10/03/2025 the report lists purchases of 11,011, 56,703, and 319,700 shares in separate tranches attributed to the fund.

Did the filing show any dispositions?

Yes; the filing indicates a disposition line that results in 5,302,810 shares held by Samsara BioCapital, L.P., reflecting prior transfers that did not change the reporting person's beneficial ownership.